Key result
c7E3 did not inhibit iliac lumen narrowing (-0.69 vs -0.99 mm, P=0.35) or intimal hyperplasia after angioplasty in atherosclerotic monkeys.
Why the study?
Does c7E3 (abciximab) prevent restenosis and intimal hyperplasia after angioplasty or stenting in atherosclerotic nonhuman primates?
Population
23 male cynomolgus monkeys with established atherosclerosis
Comparison
c7E3 bolus followed by a 48-hour infusion, plus… vs Equal volume of vehicle, plus weight-adjusted…
Design
Preclinical, randomly assigned
Follow-up
35 days
Authors
Loading...
Abciximab may not prevent restenosis via intimal hyperplasia inhibition in atherosclerotic primates; leaves open alternative mechanisms for clinical benefits.
RCT (n=23)
randomly assigned
Does c7E3 (abciximab) prevent restenosis and intimal hyperplasia after angioplasty or stenting in atherosclerotic nonhuman primates?
Absolute Event Rate: -0.69% vs -0.99%
p-value: p=0.35
In an atherosclerotic primate model, c7E3 (abciximab) did not inhibit intimal hyperplasia or improve artery wall remodeling after angioplasty or stenting, suggesting alternative mechanisms for its clinical benefits.
Deitch et al. (1998) conducted an RCT in established atherosclerosis (n=23). c7E3 vs. vehicle was evaluated on iliac lumen narrowing (LDDay35-LDPost) (p=0.35). c7E3 did not inhibit iliac lumen narrowing (-0.69 vs -0.99 mm, P=0.35) or intimal hyperplasia after angioplasty in atherosclerotic monkeys.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: